Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7249 in Patients With Hyperlipidemia
NCT07100418Phase 2Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised trial of HRS-7249 in hyperlipidemia (2 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Triglyceride Level at 28 weeks. Started Aug 2025; status: active, not recruiting.
02
Drugs
HRS-7249
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07100418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07100418.